Press releases

Company welcomes FDA statement that drug-eluting stents remain safe and effective when used for approved indications

NEJM editorial and articles describe results of two randomized clinical trials, PASSION and TYPHOON

Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...

Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population

International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent

PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems

Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system

Company also to host WCC symposia on drug-eluting stents, therapies in cardiac rhythm management and carotid artery disease

"The second quarter was a transforming one for Boston Scientific," said Jim Tobin, President and CEO

Precision™ SCS System, the first and smallest rechargeable system, achieves rapid adoption